todeposit218378659-1-
Guru 3D / Shutterstock.com
4 November 2014PharmaPeter ten Haaft

Patent protection for microorganisms

Disclosure of the invention is a requirement for a patent application. A person skilled in the art should be able to perform the invention without undue burden based on the description of the invention in the application. In general, the requirements of disclosure are met by a written description that enables the person skilled in the art to perform a claimed method or to obtain a claimed product. Where a microorganism is involved, a written description may be sufficient to perform a claimed method or to obtain a claimed (biological) product.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
22 September 2026   After a run of UK decisions going against major pharma patents on plausibility, Novartis bucked the trend with Entresto. The company’s lead counsel from Bristows explains why and what patentees can take from the ruling.
Pharma
17 September 2026   Bauer Research Foundation has alleged that the CDMO misappropriated its confidential manufacturing know-how related to NO-Cbl, an anticancer drug candidate in the pre-clinical/translational stage of development for potential human use.
Pharma
16 September 2026   A medicine reaching the end of its primary patent term does not necessarily mean the market is open to generics. The complex patent landscape surrounding semaglutide shows how secondary patents covering indications, formulations and manufacturing processes can extend competitive barriers—and why careful freedom-to-operate analysis is critical before launch, says Ana Neves of Inventa.